Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.06 CAD
Change Today -0.005 / -7.69%
Volume 70.0K
EKG On Other Exchanges
As of 1:38 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

cardiocomm solutions inc (EKG) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/2/15 - C$0.14
52 Week Low
10/15/14 - C$0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cardiocomm solutions inc (EKG) Related Businessweek News

No Related Businessweek News Found

cardiocomm solutions inc (EKG) Details

CardioComm Solutions, Inc. is engaged in the development of hardware and software for the cardiology field in the United States, Canada, and other countries. The company’s technology is used in various products for recording, viewing, analyzing, and storing electrocardiograms (ECGs) for the diagnosis and management of cardiac patients. Its software products include Global ECG Management System (GEMS), a software solution for cardiac event monitoring; GlobalCardio 3 Lead; GlobalCardio 12 Lead, a Web enabled portable ECG device that is electronic medical records (EMR) compatible; and ECG Viewer SDK. The company also offers software modules, such as GEMS Air, a live wireless ECG monitoring solution; AutoAttendant, which allows healthcare providers to focus on providing patient care; GEMS HL7 and EMR Interface that allows patient and follow-up information to be sent in an HL7 message format to other EMR systems that are HL7 compliant; GlobalCardio EMR integration that integrates with EMR and enables bidirectional movement of data; and GEMS Lite, an electronic ECG receiving system. In addition, it provides hardware products comprising HeartCheck, a handheld ECG monitors; HeartCheck PEN; QRS Diagnostic; Cardiac Science Atria ECG recorders; DR200/HE, a holter and event recorder; Burdick Atria 3100 ECG, an electrocardiogram system for private practices; Burdick Atria 6100 ECG, a portable ECG/EKG system for hospitals and cardiology clinics; GEMSTrak AF, a cardiac event recorder with atrial fibrillation auto-capture; and ECG electrodes. Further, the company offers ASP services, including C4 ECG management services. It serves hospitals, call centers, and physician’s offices through a combination of the company’s external distribution network and sales team. CardioComm Solutions, Inc. was incorporated in 1989 and is headquartered in North York, Canada.

Founded in 1989

cardiocomm solutions inc (EKG) Top Compensated Officers

Chief Executive Officer, Corporate Secretary,...
Total Annual Compensation: C$250.0K
Chief Financial Officer
Total Annual Compensation: C$30.0K
Compensation as of Fiscal Year 2013.

cardiocomm solutions inc (EKG) Key Developments

Cardiocomm Solutions Inc. Announces Availability of HeartCheck ECG PEN in Select Rexall Pharmacies

CardioComm Solutions Inc. announced the HeartCheck ECG PEN is now available on the shelves of select Rexall Pharmacies in Canada. Participating Rexall Pharmacies will display the HeartCheck ECG PEN in their diabetes over-the-counter section. In-store product literature for customers as well as pharmacists will be made available from CardioComm Solutions in the participating stores. To the concerned or motivated consumer, the HeartCheck ECG PEN will allow them to monitor their heart right at the time they experience difficult to capture or unpredictable symptoms such as racing heart rates, palpitations, dizziness or irregular heartbeats. ECG recordings can be saved and shared with the person's health care provider, or sent to the Company's SMART Monitoring ECG service for review, interpretation and confirmation of the presence of a potential cardiac arrhythmia within 30 minutes. Intended not only for those actively interested in taking control in maintaining their health, the HeartCheck PEN is also for those living with chronic conditions such as hypertension, diabetes, congestive heart disease and may help to identify the presence of atrial fibrillation and track for signs for risk of sudden cardiac death such as prolonged QRS duration and QT intervals. AF is the most common arrhythmia in developed countries and is associated with a doubling of risk for dementia, a tripling of risk for heart failure, and a 40% to 90% increased risk for overall mortality. Individuals with atrial fibrillation also have a very high risk of stroke that is 3 to 5 times greater than those without AF according to the Canadian Heart and Stroke Foundation. The HeartCheck PEN introduction into Rexall marks another important milestone in CardioComm Solution's efforts to expand sales throughout Canada. It comes at a time when the provision of managed healthcare in Canada is moving away from traditionally exclusive healthcare providers such as hospitals and when informed consumers are increasingly taking charge of managing their own health. This paradigm shift is one that pharmacies and pharmacists are playing an active role in. Through the introduction of qualified medical devices such as the HeartCheck ECG PEN, this continuing shift will serve to relieve some of the current pressures on a heavily burdened Canadian Health Care system. The HeartCheck ECG PEN device and GEMS Home software will specifically enable consumers to be proactive in managing an important aspect of their health that previously was not possible without a visit to a physician or medical testing laboratory.

Cardiocomm Solutions, Inc. Enters into Three Year Renewable, Non-Exclusive, Co-Marketing and Distribution Agreement with Braemar Manufacturing

CardioComm Solutions Inc. announced it has entered into a three year renewable, non-exclusive, co-marketing and distribution agreement with Braemar Manufacturing Ltd. Under the agreement, the parties will collaborate to develop and execute on business opportunities in the GSM based wireless ECG event/arrhythmia monitoring market globally. CardioComm Solutions develops and distributes GEMSTM WIN and GEMSTM AIR ECG software management technologies for use in the ambulatory monitoring of patients, to independent diagnostic testing facilities, hospitals and clinic groups. Braemar engineers, manufactures and sells non-invasive, transtelephonic and GSM enabled wireless ECG recording and arrhythmia detection cardiac monitors. CardioComm Solutions expects to benefit from increased sales of its GEMSTM WIN software and from customers upgrading their license to include GEMSTM AIR. Additionally, CardioComm Solutions will be provided a per-device fee for sales that are derived though CardioComm Solutions sales leads.

Cardiocomm Solutions Inc. Enters into Sales and Marketing Agreement

CardioComm Solutions Inc. announced that it has entered into a sales and marketing agreement for growing and managing the Company’s HeartCheck™ ECG related business in drug chains, mass retailers, club retailers, grocery retailers and distributors’ head offices in the USA.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKG:CN C$0.06 CAD -0.005

EKG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $49.97 USD -0.04
LifeWatch AG SFr.14.20 CHF +0.45
View Industry Companies

Industry Analysis


Industry Average

Valuation EKG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOCOMM SOLUTIONS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at